Navigating the shift from R&D to a commercially viable biopharma company presents unique challenges, especially when expanding into the European market. Our Simon-Kucher whitepaper offers essential insights for US-based biopharma companies aiming to achieve a successful transition.
Drawing from extensive research—including over 20 case studies, approximately 4,500 data points, and insights from 18 industry experts—this whitepaper identifies critical factors for a successful first drug launch in Europe and explores:
- Characteristics of First Drug Launches in Europe: Key factors for successful independent launches, including drug, disease area, and company specifics.
- Opportunities and Reasons to Commercialize: Strategic motivations for launching a drug in Europe independently.
- The Seven Secret Ingredients for Success: Essential elements that maximize value in a first drug launch.
- The Dos and Don’ts: Crucial considerations and common pitfalls when planning a company’s first product launch in Europe.
Discover how to leverage unmet medical needs, orphan drug status, and disease severity to optimize pricing and market positioning. Learn from the pitfalls of companies that failed to plan and execute their European launches effectively, and gain actionable strategies for aligning global and regional goals.
Get a copy of our whitepaper to gain a comprehensive understanding of how to effectively prepare for and execute a successful European launch and build a robust, integrated biopharma organization.
Thanks to contributions from Lukas Hirn!
